"Metolazone"

Xaqua (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparations Skip to main contentCookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites to help us deliver content from their services.Accept additional cookiesReject additional cookiesView cookies GOV.UKNavigation menuMenuSearch GOV.UKHomeDrug Safety UpdateXaqua (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparationsPrescribers and dispensers should use caution if switching patients between different metolazone preparations as the rate and extent of absorption of metolazone are formulation

Differences between metolazone preparations and safety considerations Differences between metolazone preparations and safety considerations – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice SPS - Specialist Pharmacy Service The first stop for professional medicines advice * About * Log in * Register NHS * Guidance Guidance * Guidance index services * Intrathecal administration * Manufacturing and preparation * Unlicensed medicines * Homecare * ATMPs * Clinical Trials * Medical gases * More * Less * Home * Guidance * Switching Differences between metolazone preparations and safety considerations Emma Kirk, Specialist Pharmacist - Lead Medication Safety, Medicines Use and Safety Team · Published 7 September 2022

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics To examine the decongestive effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin compared to the thiazide-like diuretic metolazone in patients hospitalized for heart failure and resistant to treatment with intravenous furosemide. A multi-centre, open-label, randomized, active-comparator trial. Patients were randomized to dapagliflozin 10 mg once daily or metolazone 5-10 mg once daily for a 3-day treatment period, with follow-up for primary and secondary endpoints until day 5 (96 hours). The primary endpoint was diuretic effect, assessed by change in weight (kg). Secondary endpoints included change in pulmonary congestion (lung ultrasound), loop diuretic efficiency (weight change per 40 mg of furosemide

Effects of Metolazone Administration on Congestion, Diuretic Response and Renal Function in Patients with Advanced Heart Failure. Advanced heart failure (HF) is a condition often requiring elevated doses of loop diuretics. Therefore, these patients often experience poor diuretic response. Both conditions have a detrimental impact on prognosis and hospitalization. This retrospective, multicenter study evaluates the effect of the addition of oral metolazone on diuretic response (DR), clinical congestion, NTproBNP values, and renal function over hospitalization phase. Follow-up analysis for a 6-month follow-up period was performed. We enrolled 132 patients with acute decompensated heart failure (ADHF) in advanced NYHA class with reduced ejection fraction (EF < 40%) taking a mean furosemide

Metolazone An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM and EffectsSummary of Use during LactationNo information is available on the amount of metolazone in breastmilk. Intense diuresis with large doses may decrease breastmilk production. Other diuretics in low doses are preferred over metolazone.Drug LevelsMaternal Levels. Relevant published information was not found as of the revision date.Infant Levels. Relevant published information was not found as of the revision

Comparing the sodium excreting efficacy of furosemide and indapamide combination against furosemide and metolazone combination in congestive heart failure patients: A randomized control trial. To compare efficacy and safety of indapamide-furosemide combination against metolazone-furosemide combination in refractory heart failure patients. The randomised controlled trial was conducted at Rehman Medical Institute, Peshawar, Pakistan, from January 1 to June 30, 2018, and comprised refractory heart failure patients who were randomised into two groups using lottery method Group 1 received intravenous furosemide 40mg Q12hr with metolazone 5mg Q24hr, while group 2 received intravenous furosemide 40mg Q12hr with indapamide 2.5mg Q24hr. Both groups were assessed for urinary sodium excretion, total

Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis Background In acute decompensated heart failure, guidelines recommend increasing loop diuretic dose or adding a thiazide diuretic when diuresis is inadequate. We set out to determine the adverse events associated with a diuretic strategy relying on metolazone or high-dose loop diuretics. Methods and Results Patients admitted to 3 hospitals using a common electronic medical record with a heart failure discharge diagnosis who received intravenous loop diuretics were studied in a propensity-adjusted analysis of all-cause mortality. Secondary outcomes included hyponatremia (sodium <135 mE q/L), hypokalemia (potassium <3.5 mE q/L) and worsening renal

Pharmacokinetic study of single- and multiple-dosing with metolazone tablets in healthy Chinese population Metolazone is a diuretic, saluretic and antihypertensive chemical compound from the quinazoline category that possesses medicinal features similar to those of other thiazide diuretic drugs. However, the pharmacokinetics of metolazone in the Chinese population has rarely been studied . This study aimed to examine the pharmacokinetic characteristics, safety characteristic, and tolerability of metolazone in healthy Chinese subjects after single and multiple doses taken orally as well as the effects that food and gender have on oral metolazone pharmacokinetic parameters. An open-label, randomized, and single- and multiple-dosing investigation was performed in healthy Chinese subjects

Acetazolamide or Metolazone in Acute Heart Failure Impact of Acute Heart Failure:According to the World Health Organization (WHO), approximately 26 million people suffer from Heart Failure (HF), with a mortality rate of up to 50% within five years of diagnosis. Acute Heart Failure (AHF) exacerbations, leading to hospitalization, are common and represent the primary cause of hospital admissions their use, though limited clinical trials exist. Pharmacological concepts guide their administration, emphasizing intravenous delivery in high doses and adjusting subsequent doses based on decongestive efficacy. Additionally, sequential tubular blockade with other diuretics like metolazone and acetazolamide is explored to enhance decongestion.Use of Metolazone and Acetazolamide:Sequential tubular blockade

Metolazone Versus Chlorothiazide in Acute Heart Failure Patients Treated with Loop Diuretics: An Updated Systematic Review and Meta-Analysis PROSPERO International prospective register of systematic reviews Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO

Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance. To assess the efficacy and safety of intravenous (IV) chlorothiazide versus oral metolazone when added to loop diuretics in patients with acute decompensated heart failure (ADHF) and loop diuretic resistance. Retrospective cohort study. Large urban academic medical center. Adults admitted with ADHF between 2005 and 2015 who had loop diuretic resistance, defined as administration of IV furosemide at a dose of 160 mg/day or higher (or an equivalent dose of IV bumetanide), during hospitalization, and who then received at least one dose of IV chlorothiazide (88 patients) or oral metolazone (89 patients) to augment diuresis. The primary

Efficacy of Intravenous Chlorothiazide for Refractory Acute Decompensated Heart Failure Unresponsive to Adjunct Metolazone. To assess the efficacy of intravenous chlorothiazide in patients with acute decompensated heart failure (ADHF) who were determined to be loop diuretic resistant and refractory to metolazone. Retrospective cohort study with patients serving as their own controls. Large , academic, tertiary care hospital. Forty-five patients with ADHF who had an inadequate response to high-dose loop diuretics and then received at least one dose of oral metolazone 5 mg or greater (metolazone index dose) followed by at least one dose of intravenous chlorothiazide 500 mg (chlorothiazide index dose) if the response to metolazone was considered inadequate, according to the institutional

Metolazone Associated Stevens Johnson Syndrome-Toxic Epidermal Necrolysis Overlap Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe mucocutaneous disease with high mortality rate. It is characterised by severe necrosis and detachment of the epidermis. Drugs are the most common triggering agent for SJS/TEN. These are commonly reported with the use of aromatic antiepileptics, antiretrovirals, allopurinol, NSAID'S and sulfonamide antibiotics. Non antibiotic sulfonamides rarely cause SJS/TEN. Metolazone is a well known diuretic and is extensively used by clinicians. Although this drug is in market for last several decades, no case of SJS/TEN has been reported till date. We report a rare case of metolazone induced SJS/TEN overlap in a 55-year-old lady.

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure The primary objective of the study is to determine efficacy of metolazone as synergistic therapy with Lasix in patients with acute decompensated heart failure. This will be a multicenter double blinded randomized placebo- controlled pilot study of the addition of 5 mg of metolazone per day for 2 days compared to placebo in patients admitted with acute decompensated heart failure. AS DESCRIBED BY THE PRINCIPAL INVESTIGATOR (DR. HEYWOOD): The primary objective of the study is to determine efficacy of metolazone as synergistic therapy with Lasix in patients with acute decompensated heart failure. This will be a multicenter double blinded randomized placebo- controlled pilot study of the addition of 5 mg of metolazone per day

Use of metolazone as an adjunct to loop diuretics in diuretic resistant acute heart failure: A systematic review and meta-analysis Use of metolazone as an adjunct to loop diuretics in diuretic resistant acute heart failure: A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good

Metolazone vs. Vasopressin Antagonists as Adjuvant Diuretic Therapy in Heart Failure Exacerbation: A Systematic Review and Meta-Analysis of Outcomes PROSPEROInternational prospective register of systematic reviews Print | PDFMetolazone vs. Vasopressin Antagonists as Adjuvant Diuretic Therapy in Heart Failure Exacerbation: A Systematic Review and Meta-Analysis of OutcomesMatthew Kaye, Mohamad content. Therefore, automatically published records should be treated as any other PROSPERO registration. Further detail is provided here.CitationMatthew Kaye, Mohamad Kalot, Ronak Bahuva, Ronak Bharucha, Anna Jacquinot, Cody Elkhechen, Mohamad Kaki, Rohan Pandey, Paras Mehmood, Kristie Nasr, Danny Ram. Metolazone vs. Vasopressin Antagonists as Adjuvant Diuretic Therapy in Heart Failure Exacerbation

-robust evidence that addition of a thiazide or thiazide-like diuretic (metolazone) may be beneficial. The proposed study would aim to resolve this uncertainty and guide the management of a difficult clinical problem. 2.3 2.3 Intra-aortic balloon counter-pulsation Intra-aortic balloon counter-pulsation In people with acute heart failure and hypoperfusion syndrome, is the use of intra-aortic balloon

of diuretics and concomitant use of other drugs that increase the risk of potassium depletion or cardiac dysrhythmias can increase the risk of cardiovascular events and mortality [Lin, 2021]. * Thiazide and thiazide-like diuretics include bendroflumethiazide, chlortalidone, hydrochlorothiazide, indapamide, metolazone, and xipamide [BNF, 2024]. * Loop diuretics include bumetanide, furosemide and torsemide

hypokalaemia (potentially increasing the risk of torsade de pointes) when given with these drugs. The manufacturer makes no recommendation. * Corticosteroids — concomitant administration can increase the risk of hypokalaemia. * Diuretics such as bendroflumethiazide, bumetanide, furosemide, indapamide, and metolazone — concomitant administration can increase the risk of hypokalaemia. * Digoxin — concomitant

distal to the loop of Henle, in the hypertrophied distal convoluted tubule, at chlorothiazide’s site of action. Chlorothiazide is a thiazide diuretic, which acts on the NaCl cotransporter (NCC) in the DCT.1,6 Commonly used thiazide diuretics include chlorothiaizde and hydrochlorothiazide, and commonly used thiazide-like diuretics include chlorthalidone, indapamide, and metolazone.6 In patients chronically treated with loop diuretics, we can use thiazide and thiazide-like diuretics (which I will refer to collectively as “thiazides” for brevity) synergistically with loop diuretics to overcome the diuretic resistance arising from DCT-hypertrophy, a strategy termed “sequential nephron blockade.” Metolazone is most commonly the diuretic of choice to pair with loop diuretics.7–9 Multiple case series